Clinical

Specific dosing regimens of treatments prescribed by blood specialists have not been widely studied, despite the advent of newer hemophilia therapies, the researchers said.

A substantial proportion of families of privately insured children with sickle cell anemia pay more than $100 for essential stroke screenings, a high-value service.

With both biologics and Janus kinase (JAK) inhibitors available to treat atopic dermatitis, providers have more options for patients, said Emma Guttman-Yassky, MD, PhD, FAAD, of Mount Sinai.

In a real-world clinical setting, tildrakizumab demonstrated safety and satisfaction among patients with moderate-to-severe plaque psoriasis.

Posters presented at the American Academy of Dermatology 2023 Annual Meeting provided a snapshot of disparities in dermatology care, both in terms of geographic differences in access to care and collection of race/ethnicity data in clinical trials.

A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.

Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.

The measure will allow for a more complete picture of treatment burden and how it affects things like health-related quality of life and adherence, explained researchers.

There are certain considerations when choosing which patient is the best fit for a biologic to treat hidradenitis suppurativa, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.

Once thought of as the result of an imbalance in bodily humors, inflammatory skin diseases are now understood to arise from types of immune responses, opening the door to targeted therapies and personalized medicine, according to speakers at the American Academy of Dermatology 2023 Annual Meeting.

Investigators said the Mortality in TTP Score (MITS) was effective at characterizing the risk of death in patients hospitalized with thrombotic thrombocytopenic purpura (TTP).

Amid a packed roster of of late-breaking research at the American Academy of Dermatology 2023 Annual Meeting, investigators presented findings from long-term extensions of the Topical Ruxolitinib Evaluation in Vitiligo phase 3 studies.

Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.

Speakers at the American Academy of Dermatology 2023 Annual Meeting highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.

The Chinese report details the case of a 6-year-old female patient with type 1 SMA who was successfully weaned off prolonged invasive ventilation after beginning treatment with nusinersen.

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer.

At the American Academy of Dermatology annual meeting there will be multiple presentations on hot topics and the latest advances in microneedling, explained Monica Li, MD, clinical instructor, Department of Dermatology and Skin Science, University of British Columbia.

Different methods of DNA collection and needle sizes led to varied next-generation sequencing success rates among patients with lung cancer in a recent study.

A symposium at the American Academy of Dermatology 2023 Annual Meeting convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.

The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion.

The majority of CAR T-cell therapy recipients developed a humoral immune response to vaccination against SARS-CoV-2 in a recent study, with a more robust vaccine schedule linked to higher antibody titers.

The Skin Pain Numeric Rating Scale, Worst-Itch Numeric Rating Scale, and Dermatology Life Quality Index were evaluated for their content validity, fit-for-purpose, and psychometric and measurement properties among patients with the chronic skin disease being treated with dupilumab.

Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.

Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.

Prior to this study, explained researchers, data on the long-term course of osteoporosis, as evaluated through bone mineral density (BMD) in these patients, have been lacking.

There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found.

Key opinion leaders highlight barriers to MDR HIV treatment adherence.

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

Optimizing utilization of sacubitril/valsartan for treatment of heart failure could improve provider performance in the Bundled Payments for Care Improvement initiative and the Medicare Shared Savings Program.

John L. Marshall, MD, provides insight into the SUNLIGHT study findings presented during the 2023 ASCO Gastrointestinal Cancers Symposium.